( trials havealso been published in N...)The Genesis of Gendicine: The Story Behind the First Gene Therapy

BPI: Are there any side effects?

Peng: Clinical results indicate that Gendicine is safe and efficacious. Some patients experienced self-limiting Grade I and II fevers lasting approximately three hours. No other serious side effects were observed.

BPI: Is Gendicine a wide-spectrum anticancer agent?

Peng: In clinical trials, Gendicine has been used to successfully treat cancers of the digestive tract (esophageal, gastric, intestine, liver, pancreas, gallbladder, rectum), lung cancer, sarcoma, thyroidgland cancer, breast cancer, cervical cancer, and ovarian cancer. Although Gendicine has not been formally approved by SFDA for indications other than HNSCC, terminal patients with no other avenue of treatment have been allowed, on a case-by-case basis, to receive Gendicine with permission from the SFDA, along with a request from the patient, the patients family, and the agreement of the patients doctor. We also insist that the patient, family, and the doctor-in-charge carefully read and endorse the informed consent forms.

BPI: What is the incidence of relapse?

Peng: During more than three years of follow-up for the twelve patients with midto- late-stage laryngeal cancer who received Gendicine therapy in phase 1 clinical trials, no patient has relapsed. By contrast, among patients who received only surgery, the three-year relapse rate is approximately 30%.

BPI: What is the duration of treatment?

Peng:
'"/>

Source: